Black Diamond Therapeutics (BDTX) Insider Trading & Ownership $2.16 -0.12 (-5.26%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.20 +0.04 (+2.08%) As of 02/21/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Black Diamond Therapeutics (NASDAQ:BDTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.87%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$22.55 MNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$167,500.00 Get BDTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Black Diamond Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BDTX Insider Buying and Selling by Quarter Black Diamond Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/17/2023Growth N V BiotechMajor ShareholderBuy400,000$2.34$936,000.00 7/5/2023Ali BehbahaniDirectorBuy1,000,000$5.00$5,000,000.00 6/30/2023Growth N V BiotechMajor ShareholderBuy1,000,000$5.00$5,000,000.00 6/27/2023David M EpsteinInsiderSell25,000$6.70$167,500.00 6/27/2023Growth N V BiotechMajor ShareholderBuy1,740,000$5.49$9,552,600.00 10/27/2022Growth N V BiotechMajor ShareholderBuy191,678$1.87$358,437.86 10/21/2022Growth N V BiotechMajor ShareholderBuy87,850$1.51$132,653.50 10/19/2022Growth N V BiotechMajor ShareholderBuy77,689$1.32$102,549.48 6/29/2022Fang NiInsiderBuy25,000$2.44$61,000.00 4/27/2022Growth N V BiotechMajor ShareholderBuy150,000$2.66$399,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/18/2022Growth N V BiotechMajor ShareholderBuy150,000$3.29$493,500.00 4/12/2022Growth N V BiotechMajor ShareholderBuy150,000$3.42$513,000.00 (Data available from 1/1/2013 forward) BDTX Insider Trading Activity - Frequently Asked Questions Who is on Black Diamond Therapeutics's Insider Roster? The list of insiders at Black Diamond Therapeutics includes Ali Behbahani, David M Epstein, Fang Ni, and Growth N V Biotech. Learn more on insiders at BDTX. What percentage of Black Diamond Therapeutics stock is owned by insiders? 8.87% of Black Diamond Therapeutics stock is owned by insiders. Learn more on BDTX's insider holdings. Which Black Diamond Therapeutics insiders have been buying company stock? The following insiders have purchased BDTX shares in the last 24 months: Ali Behbahani ($5,000,000.00), and Growth N V Biotech ($15,488,600.00). How much insider buying is happening at Black Diamond Therapeutics? Insiders have purchased a total of 4,140,000 BDTX shares in the last 24 months for a total of $20,488,600.00 bought. Which Black Diamond Therapeutics insiders have been selling company stock? The following insider sold BDTX shares in the last 24 months: David M Epstein ($167,500.00). How much insider selling is happening at Black Diamond Therapeutics? Insiders have sold a total of 25,000 Black Diamond Therapeutics shares in the last 24 months for a total of $167,500.00 sold. Black Diamond Therapeutics Key ExecutivesDr. Mark A. Velleca M.D. (Age 60)Ph.D., CEO, President & Chairman Compensation: $795.98kDr. David M. Epstein Ph.D. (Age 65)Co-Founder & Director Compensation: $969.69kDr. Fang Ni Pharm.D. (Age 37)CFO, Principal Financial Officer and Chief Business Officer Compensation: $665.98kDr. Sergey Yurasov M.D. (Age 55)Ph.D., Chief Medical Officer Compensation: $718.92kDr. Elizabeth Buck Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Compensation: $340.47kMr. Brent Hatzis-Schoch Esq. (Age 59)J.D., COO & General Counsel Compensation: $683.29kMs. Elizabeth L. Montgomery (Age 52)Chief People Officer Ms. Melanie Morrison (Age 49)Chief Development Officer Ms. Erika Jones (Age 39)Senior VP of Finance & Corporate Controller More Insider Trading Tools from MarketBeat Related Companies Xeris Biopharma Insider Ownership Tectonic Therapeutic Insider Ownership MeiraGTx Insider Ownership Mineralys Therapeutics Insider Ownership Entrada Therapeutics Insider Ownership Cartesian Therapeutics Insider Ownership Humacyte Insider Ownership Arcturus Therapeutics Insider Ownership KalVista Pharmaceuticals Insider Ownership ProKidney Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:BDTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
